表紙
市場調查報告書

全球病毒載體及質體DNA製造市場:產品類型,用途,各地區 - 成長,趨勢,預測

Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, and Forecast (2019 - 2024)

出版商 Mordor Intelligence LLP 商品編碼 629143
出版日期 內容資訊 英文 115 Pages
商品交期: 2-3個工作天內
價格
全球病毒載體及質體DNA製造市場:產品類型,用途,各地區 - 成長,趨勢,預測 Viral Vector and Plasmid DNA Manufacturing Market - Growth, Trends, and Forecast (2019 - 2024)
出版日期: 2019年04月01日內容資訊: 英文 115 Pages
簡介

本報告提供全球病毒載體及質體DNA製造市場相關調查,彙整市場概要和各產品類型,各用途,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 簡介

第2章 調查方法

第3章 摘要整理

第4章 主要推論

第5章 市場概要

  • 目前市場方案
  • 波特五力分析

第6章 促進要素,阻礙要素,機會,課題分析

  • 推動市場的要素
  • 阻礙市場的要素
  • 機會
  • 主要課題

第7章 市場區隔

  • 各產品類型
    • 質體DNA
    • 病毒載體
    • 非病毒載體
  • 各用途
    • 癌症
    • 遺傳性疾病
    • 病毒感染
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第8章 競爭環境

  • 合併·收購分析
  • 協定,聯合,聯盟
  • 新產品上市

第9章 主要加入企業

  • Fujifilm Diosynth Biotechnologies
  • Sanofi
  • Spark Therapeutics
  • Uniqure
  • Massbiologics
  • Finvector
  • Brammer Bio
  • Cell and Gene Therapy Catapult
  • Cobra Biologics
  • 其他

第10章 市場未來

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 49197

Market Overview

The viral vector and plasmid DNA manufacturing market is expected to grow with a healthy CAGR of nearly 18.15% during the forecast period, 2019-2024.

  • Viral vectors and plasmid DNA are products of gene therapy, which are used for the treatment of a large number of diseases. The advantages of gene vaccines and gene therapy over conventional vaccines and therapies include the ability to induce a wide range of immune response types.
  • Several players, including pharmaceutical companies, research institutes, contract manufacturing organizations, and non-profit organizations, are playing a critical role in the development and production of these vectors.
  • A number of clinical studies are being conducted on viral vectors and plasmid DNA manufacturing, which emphasize the potential of gene therapy to address important medical needs, and have initiated a surge of investments in drug development and commercialization of these therapies.
  • Factors, such as technological advancements to mitigate challenges posed by conventional methods of vector production, increase in the number of clinical studies, and a growing number of gene therapy candidates, coupled with their rapid progression through various phases of clinical development, are primarily driving the demand for viral vector and plasmid DNA manufacturing.

Scope of the Report

As per the scope of this report, viral vectors and plasmid DNA are the products of gene therapy, which are used for the treatment of several diseases, such as Alzheimer's disease, Parkinson's disease, and rheumatoid arthritis. Gene therapies and other therapies that require genetic modification include the introduction of therapeutic DNA/gene into a patient's body or cell. This process is accomplished by the use of vectors. Over the past few decades, various viral and non-viral vectors have been developed and standardized for this purpose. Moreover, viral vectors and plasmid DNA are known to reduce the cost of treatment and help in decreasing repeated administrations of medications

Key Market Trends

Plasmid DNA Segment is Expected to Register Robust Growth.

A plasmid DNA is a small DNA molecule within a cell that is different from the chromosomal DNA, which can replicate independently. Plasmid DNA is currently gaining increasing importance, due to the clinical research applications in gene therapy and genetic vaccination. The demand and therapeutic applications for plasmid DNA (pDNA) have rapidly grown and expanded. Plasmid DNA manufacturing is used for indirect and direct clinical applications. For the direct gene transfer into the human body, good manufacturing practice (GMP)-grade plasmid DNA is being required. The plasmid DNA manufacturing is invariably outsourced to the specialized manufacturers using the in-house platform processes.

North America Dominates the Market in Terms of Revenue Generated

Currently, North America is witnessing a rapid growth in the market studied, followed by Europe. The United States has been a major destination for all the recent advancements in the field of medicine. Increasing investments in gene therapy products in the United States have led to the growth of the market studied in recent years. In the United States, regulatory encouragement and patient advocacy have pushed rare disease clinical research to the center stage. The significant incentives offer through Orphan Drugs Act (United States) and the Orphan Medicinal Products Regulations (European Union) have encouraged pharmaceutical and biotechnology companies to consider the development of rare disease medicines as a potentially profitable endeavour.

Competitive Landscape

The market studied is still in its infant stage. Hence, the increasing focus is mainly on the development of innovative products. Key market players include Brammer Bio, Cobra Biologics, FinVector Vision Therapies, Fujifilm Diosynth Biotechnologies, MassBiologics, SIRION Biotech, Merck KGaA Inc, Thermo Fisher Scientific, and Uniqure NV, among others.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
    • 4.2.2 Increasing Number of Clinical Studies and Availability of Funding for Gene Therapy Development
    • 4.2.3 Potential Applications in Novel Drug Delivery Approaches
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Gene Therapies
    • 4.3.2 Challenges in Viral Vector Manufacturing Capacity
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Plasmid DNA
    • 5.1.2 Viral Vector
    • 5.1.3 Non-viral Vector
  • 5.2 By Application
    • 5.2.1 Cancer
    • 5.2.2 Genetic Disorder
    • 5.2.3 Infectious Disease
    • 5.2.4 Other Diseases
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 US
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 UK
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East & Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East & Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Brammer Bio
    • 6.1.2 Cobra Biologics
    • 6.1.3 Cell and Gene Therapy Catapult
    • 6.1.4 FinVector Vision Therapies
    • 6.1.5 Fujifilm Diosynth Biotechnologies
    • 6.1.6 MassBiologics
    • 6.1.7 SIRION Biotech
    • 6.1.8 Merck KGaA Inc.
    • 6.1.9 Thermo Fisher Scientific
    • 6.1.10 Uniqure NV

7 MARKET OPPORTUNITIES AND FUTURE TRENDS